Evidence map›Paper›PMID 41449271›Full record

ArticleJournal of natural medicines2026

Cyclosebistine A, a unique anti-malarial bisindole alkaloid from Catharanthus roseus.

Yusuke Hirasawa, Risa Domon, Haruto Yoshimura, Ruka Imai, Marin Shiraishi, Nahoko Uchiyama, Hajime Honma, Hiroshi Morita

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yusuke HirasawaFaculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan.
Risa DomonFaculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan.
Haruto YoshimuraFaculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan.
Ruka ImaiFaculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan.
Marin ShiraishiFaculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan.
Nahoko UchiyamaNational Institute of Health Sciences, 3‑25‑26 Tonomachi, Kawasaki‑Ku, Kawasaki, 210‑9501, Kanagawa, Japan.
Hajime HonmaSection of Global Health, Division of Public Health, Department of Hygiene and Public Health, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan.
Hiroshi MoritaFaculty of Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41 Shinagawa-ku, Tokyo, 142-8501, Japan. moritah@hoshi.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new dimeric indole alkaloid, cyclosebistine A consisting of an aspidosperma type and a modified iboga type through [2 + 2] cycloaddition was isolated from Catharanthus roseus, and the structure including absolute stereochemistry was determined on the basis of the 2D NMR data and CD calculation. Cyclosebistine A showed reasonably potent anti-malarial activity.

Indexed as

AntimalarialsCatharanthusIndole AlkaloidsPlant ExtractsMagnetic Resonance SpectroscopyMolecular StructurePlasmodium falciparumAntimalarialsIndole AlkaloidsPlant ExtractsAnti-malarial activityBisindole alkaloidCatharanthus roseusCyclosebistine A

Identifiers

PMID41449271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.